Findings

What do systematic reviews say?

49 questions · 63 findings · 6 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 17 · 27%GRADE not reported 0 · 0%Very low 21 · 33.3%Low 20 · 31.7%Moderate 5 · 7.9%High 0 · 0%

Intratympanic corticosteroids vs no treatment or versus placebo

Ear pain: at the time of injection · sudden sensorineural hearing loss

1 finding from 1 review

Intratympanic corticosteroids for sudden sensorineural hearing loss 2022 · Cochrane Headline outcomes only
no estimate extracted
44 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Psychophysical testing for recovery of sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

It is very uncertain whether systemic corticosteroids plus intranasal… changes psychophysical testing for recovery of sense of smell compared with no intervention (very low certainty).

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 11 [0.7, 173.66]
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Intervention not reported

Use of corticosteroids (proportion of patients using corticosteroids) · children with PFAPA

The intervention may leads to lower use of corticosteroids (proportion of patients using corticosteroids) (low certainty).

1 finding from 1 review

Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA) 2019 · Cochrane Headline outcomes only
RR 0.58 [0.37, 0.92]
1 study · 39 participants
Low